Transcriptomic evaluation of canine suspension-shipped and pre-plated hepatocytes: Comparison to liver

Toxicology Mechanisms and Methods

Volumn 23, Issue 7, 2013, Pages 479-490

  Ditewig, Amy C ^a   Cugier, David J ^a   Liguori, Michael J ^a   Yang, Yi ^a   Blomme, Eric A G ^a  

^a ABBVIE INC   (United States)

Author keywords

Cytochrome P450; Gene expression; Methods; Toxicology

Indexed keywords

CARBON DIOXIDE; CYTOCHROME P450 2B; CYTOCHROME P450 3A; DRUG METABOLIZING ENZYME; MESSENGER RNA; PHENOBARBITAL; RIFAMPICIN; TRANSCRIPTOME; XENOBIOTIC AGENT;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CELL SUSPENSION; CONTROLLED STUDY; DESCRIPTIVE RESEARCH; DOWN REGULATION; GENE EXPRESSION; GENETIC REGULATION; IN VITRO STUDY; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; TRANSCRIPTOMICS; XENOBIOTIC METABOLISM;

ANIMALS; BASE SEQUENCE; CRYOPRESERVATION; CYTOCHROME P-450 ENZYME SYSTEM; DNA PRIMERS; DOGS; HEPATOCYTES; ISOENZYMES; LIVER; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTOME;

EID: 84883443424     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.3109/15376516.2013.796031     Document Type: Article

References (37)

1. Amacher DE. (2010). The effects of cytochrome P450 induction by xenobiotics on endobiotic metabolism in pre-clinical safety studies. Toxicol Mech Methods 20:159-66.
2. Bailly-Maitre B, De Sousa G, ZUcchini N, et al. (2002). Spontaneous apoptosis in primary cultures of human and rat hepatocytes: molecular mechanisms and regulation by dexamethasone. Cell Death Differ 9: 945-55.
3. Bhatia SN, Balis UJ, Yarmush ML, Toner M. (1999). Effect of cell-cell interactions in preservation of cellular phenotype: cocultivation of hepatocytes and nonparenchymal cells. FASEB J 13:1883-900.
4. Blomme EA, Yang Y, Waring JF. (2009). Use of toxicogenomics to understand mechanisms of drug-induced hepatotoxicity during drug discovery and development. Toxicol Lett 186:22-31.
5. Botts S, Ennulat D, Francke-Carroll S, et al. (2010). Introduction to hepatic drug metabolizing enzyme induction in drug safety evaluation studies. Toxicol Pathol 38:796-8.
6. Chandra P, Brouwer KL. (2004). The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm Res 21: 719-35.
7. Chen J, Tran C, Xiao L, et al. (2009). Co-induction of CYP3A12 and 3A26 in dog liver slices by xenobiotics: species difference between human and dog CYP3A induction. Drug Metab Lett 3: 61-6.
8. Dunn JC, Yarmush ML, Koebe HG, Tompkins RG. (1989). Hepatocyte function and extracellular matrix geometry: long-term culture in a sandwich configuration. FASEB J 3:174-7.
9. Elaut G, Henkens T, Papeleu P, et al. (2006). Molecular mechanisms underlying the dedifferentiation process of isolated hepatocytes and their cultures. Curr Drug Metab 7:629-60.
10. Evans WE, Relling MV. (1999). Pharmacogenomics: translating functional genomics to rational therapeutics. Science 286:487-91.
11. Food and Drug Administration Center for Drug Evaluation and Research. (2010). Guidance for industry: M3 (R2) nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. Maryland: FDA.
12. Fraser DJ, Feyereisen R, Harlow GR, Halpert JR. (1997). Isolation, heterologous expression and functional characterization of a novel cytochrome P450 3A enzyme from a canine liver cDNA library. J Pharmacol Exp Ther 283:1425-32.
13. Gomez-Lechon MJ, Lahoz A, Gombau L, et al. (2010). In vitro evaluation of potential hepatotoxicity induced by drugs. Curr Pharm Des 16:1963-77.
14. Graham RA, Tyler LO, Krol WL, et al. (2006). Temporal kinetics and concentration-response relationships for induction of CYP1a, CYP2b, and CYP3A in primary cultures of beagle dog hepatocytes. J Biochem Mol Toxicol 20:69-78.
15. Gross-Steinmeyer K, Stapleton PL, Tracy JH, et al. (2005). Influence of Matrigel-overlay on constitutive and inducible expression of nine genes encoding drug-metabolizing enzymes in primary human hepatocytes. Xenobiotica 35:419-38.
16. Hewitt NJ, de Kanter R, Lecluyse E. (2007). Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry-do they comply with FDA recommendations? Chem Biol Interact 168:51-65.
17. Hoffmaster KA, Turncliff RZ, Lecluyse EL, et al. (2004). P-glycoprotein expression, localization, and function in sandwich-cultured primary rat and human hepatocytes: relevance to the hepatobiliary disposition of a model opioid peptide. Pharm Res 21:1294-302.
18. Klaassen CD, Lu H. (2008). Xenobiotic transporters: ascribing function from gene knockout and mutation studies. Toxicol Sci 101: 186-96.
19. Lecluyse EL. (2001). Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci 13:343-68.
20. Lecluyse EL, Alexandre E, Hamilton GA, et al. (2005). Isolation and culture of primary human hepatocytes. Methods Mol Biol 290: 207-29.
21. Lecluyse EL, Witek RP, Andersen ME, Powers MJ. (2012). Organotypic liver culture models: meeting current challenges in toxicity testing. Crit Rev Toxicol 42:501-48.
22. Li YQ, Prentice DA, Howard ML, et al. (1999). The effect of hormones on the expression of five isoforms of UDP-glucuronosyltransferase in primary cultures of rat hepatocytes. Pharm Res 16:191-7.
23. Liguori MJ, Lee C-H, Liu H, et al. (2012). AhR activation underlies the CYP1A autoinduction by A-998679 in rats. Front Genet 3:213. doi: 10.3389/fgene.2012.00213.
24. Luttringer O, Theil FP, Lave T, et al. (2002). Influence of isolation procedure, extracellular matrix and dexamethasone on the regulation of membrane transporters gene expression in rat hepatocytes. Biochem Pharmacol 64:1637-50.
25. Madan A, Graham RA, Carroll KM, et al. (2003). Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 31:421-31.
26. Messner S, Agarkova I, Moritz W, Kelm JM. (2013). Multi-cell type human liver microtissues for hepatotoxicity testing. Arch Toxicol 87: 209-13.
27. Mooney D, Hansen L, Vacanti J, et al. (1992). Switching from differentiation to growth in hepatocytes: control by extracellular matrix. J Cell Physiol 151:497-505.
28. Obach RS. (2009). Predicting drug-drug interactions from in vitro drug metabolism data: challenges and recent advances. Curr Opin Drug Discov Devel 12:81-9.
29. Olson H, Betton G, Robinson D, et al. (2000). Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32:56-67.
30. Ortiz de Montellano PR. (1995). Cytochrome P450: structure, mechanism, and Biochemistry. New York: Plenum Press.
31. Papeleu P, Vanhaecke T, Henkens T, et al. (2006). Isolation of rat hepatocytes. Methods Mol Biol 320:229-37.
32. Richert L, Liguori MJ, Abadie C, et al. (2006). Gene expression in human hepatocytes in suspension after isolation is similar to the liver of origin, is not affected by hepatocyte cold storage and cryopreservation, but is strongly changed after hepatocyte plating. Drug Metab Dispos 34:870-9.
33. Sidhu JS, Liu F, Omiecinski CJ. (2004). Phenobarbital responsiveness as a uniquely sensitive indicator of hepatocyte differentiation status: requirement of dexamethasone and extracellular matrix in establishing the functional integrity of cultured primary rat hepatocytes. Exp Cell Res 292:252-64.
34. Tuschl G, Mueller SO. (2006). Effects of cell culture conditions on primary rat hepatocytes-cell morphology and differential gene expression. Toxicology 218:205-15.
35. Vinken M, Decrock E, Vanhaecke T, et al. (2012). Connexin43 signaling contributes to spontaneous apoptosis in cultures of primary hepatocytes. Toxicol Sci 125:175-86.
36. Yang Y, Ciurlionis R, Kowalkowski K, et al. (2012). N-vinylpyrrolidone dimer, a novel formulation excipient, causes hepatic and thyroid hypertrophy through the induction of hepatic microsomal enzymes in rats. Toxicol Lett 208:82-91.
37. Zurlo J, Arterburn LM. (1996). Characterization of a primary hepatocyte culture system for toxicological studies. In Vitro Cell Dev Biol Anim 32:211-20.